Scientific Board

Synergix Ltd. has established a Scientific Advisory Board comprised of the key thought leaders in the areas of drug design, molecular modeling and medicinal chemistry.

• Prof. Gordon M. Crippen University of Michigan, Ann Arbor, USA
• Prof. Toshio Fujita Fujitsu Kansai Laboratory, Osaka, Japan
• Prof. Johann Gasteiger Erlangen University, Erlangen, Germany
• Dr. Konrad Koehler Karo Bio Novum Ltd., Huddinge, Sweden
• Dr. Patrick Y. Lam Bristol-Myers Squibb Company, Wilmington, Delaware, USA
• Prof. Alexander Levitzki The Hebrew University, Jerusalem, Israel
• Dr. Gerald M. Maggiora Pharmacia & Upjohn, Kalamazoo, Michigan, USA
• Prof. Raphael Mechoulam The Hebrew University, Jerusalem, Israel
• Prof. Laszlo Pallos Hungarian Chemical Society, Budapest, Hungary
• Prof. Robert S. Pearlman University of Texas at Austin, Texas, USA
• Prof. Roberto Pellicciari University di Perugia, Perugia, Italy
• Prof. Pierre Potier Institut de Chimie des Substances Naturelles CNRS, Gif, France
• Dr. Tomi K. Sawyer Ariad Pharmaceuticals Inc., Cambridge, Massachusetts, USA
• Dr. Jonathan M. Schapiro Stanford University School of Medicine, California, USA
• Prof. Harold Scheraga Cornell University, Ithaca, New York, USA
• Prof. Brian Shoichet Northwestern University Medical School, Chicago, Illinois, USA
• Prof. Hendrik Timmerman Leiden University, Amsterdam, The Netherlands
• Prof. Jan P. Tollenaere Janssen Research Foundation, Beerse, Belgium
• Prof. David J. Triggle State University of New York, Buffalo, New York, USA
• Prof. Jacques Weber University of Geneva, Geneva, Switzerland
• Prof. Paul A. Wender Stanford University, Stanford, California, USA
• Dr. Alexander Wlodawer National Cancer Institute, Frederick, Maryland, USA
• Prof. Shoshana Wodak University of Brussels, Brussels, Belgium
• Prof. Albert Zilkha The Hebrew University, Jerusalem, Israel